2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. Post author:alarpharm Post published:3 . 5 . 2021 Post category:Media releases You Might Also Like 2023/08/21 ALA-3000 has received the Notice of Eligibility of Grant from Intellectual Property Office of Singapore (IPOS) after the examination.(Patent Application No. 11202104792S) 23 . 8 . 2023 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022 2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia. 25 . 8 . 2020 2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582 6 . 12 . 2022 2023/07/25 ALA-3000 Received the patent, KETAMINE PAMOATE AND USE THEREOF from China National Intellectual Property Administration (CNIPA) , NO : 202080007207.5 26 . 7 . 2023
2023/08/21 ALA-3000 has received the Notice of Eligibility of Grant from Intellectual Property Office of Singapore (IPOS) after the examination.(Patent Application No. 11202104792S) 23 . 8 . 2023
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582 6 . 12 . 2022
2023/07/25 ALA-3000 Received the patent, KETAMINE PAMOATE AND USE THEREOF from China National Intellectual Property Administration (CNIPA) , NO : 202080007207.5 26 . 7 . 2023
